Vous avez cherché: ufh (Anglais - Maltais)

ufh/ enox
sit ta ’ fsada

arm a ufh/enox
fergħa a ufh/enox

intravenous unfractionated heparin (ufh):
eparina mhux frazzjonata ġol-vini (ufh - unfractionated heparin):

ufh/enox1 + gp iib/iiia inhibitor (%)
ufh/enox1 + inhibitur ta’ gp iib/iiia (%)

the baseline characteristics and duration of fondaparinux treatment were comparable in both ufh groups.
il-karatteristiċi fil-linja bażi u t-tul ta’ żmien ta’ kura b’fondaparinux kienu jixxiebħu fiż-żewġ gruppi ta’ ufh.

d last dose of fondaparinux, the median dose of ufh was 8000 iu and the incidence of major bleeding
f’ dawk il- pazjenti li għaddew minn pci mhux primarju 6- 24 siegħa wara l- aħħar doża ta ’ fondaparinux, id- doża medja ta ’ ufh kienet ta ’ 8000 iu u l- inċidenza ta ’ ħa fsada maġġuri kienet ta ’ 2% (2/ 98).

in arm a of the acuity trial, ufh or enoxaparin was administered in accordance with the relevant guidelines for the management of acs in patients with ua and nstemi.
f’fergħa a tal-prova ta’ acuity, ingħataw ufh jew enoxaparin skond il-linji gwida relevanti għall- ġestjoni ta’ acs f’pazjenti b’ua u b’nstemi.

a total of 17 deaths occurred after subacute stent thrombosis, 3 in the bivalirudin arm and 14 in the ufh plus gp iib/iiia arm.
total ta’ 17-il mewta seħħew wara trombożi stent subakuti, 3 fil-grupp ta’ bivalirudin u 14 fil-grupp ta’ ufh flimkien ma’ inhibitur ta’ gp iib/iiia.

randomised patients could have been pre-treated with ufh during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were excluded.
pazjenti li ntgħażlu bla ħsieb jista’ jkun li ġew trattati qabel b’ufh waqt il-fażi ta’ screening iżda ġew esklużi pazjenti trattati għal iżjed minn 24 siegħa b’doża terapewtika ta’ antikoagulant jew pazjenti li kellhom pressjoni għolja mhux kontrollata.

36 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of dvt were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of ufh in the treatment of pe were 5.5%, 6.6% and 7.4%, respectively.
39 rakkomandat ta ’ enoxaparin fit- trattament ta ’ dvt kienu ta ’ 2. 5%, 3. 6% u 8. 3% rispettivament, u l - każi f’ pazjenti li jieħdu d- dożaġġ rakkomandat ta ’ ufh fit- trattament ta ’ pe kienu ta ’ 5. 5%, 6. 6% and 7. 4% rispettivament.